Protocol Ledger

NCT05067127 · Phase III · COMPLETED

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Interventional Phase III clinical trial protocol NCT05067127 sponsored by Apellis Pharmaceuticals in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-12 Enrollment: 124 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05067127
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)124 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05067127
Protocol FieldVerified Registry Value
NCT IdentifierNCT05067127
Consolidated Lead SponsorApellis Pharmaceuticals
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment124 participants (ACTUAL)
Registered Start Date2021-11-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI